Filtered By:
Cancer: Glioma

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 625 results found since Jan 2013.

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
Drug Deliv. 2023 Dec;30(1):1-13. doi: 10.1080/10717544.2022.2152911.ABSTRACTTemozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties. O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme, which can repair the DNA damage caused by TMZ. A large number of clinical data show that reducing the expression of MGMT can enhance the chemotherapeutic efficacy of TMZ. Therefore, in order to improve the resistance of glioma to TMZ, an angiopep-2 (A2) modified nanoprodrug of polytemozolomide (P(TMZ)n) tha...
Source: Drug Delivery - December 29, 2022 Category: Drugs & Pharmacology Authors: Haoyue Xu Yongkang Zhang Linfeng Li Yanhong Ren Feng Qian Lansheng Wang Hongwei Ma Ankang Quan Hongmei Liu Rutong Yu Source Type: research

Oncogenic < em > BRAF < /em > < sup > V600E < /sup > induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase
Neural Regen Res. 2023 Jul;18(7):1613-1622. doi: 10.4103/1673-5374.361516.ABSTRACTActivating V600E in v-Raf murine sarcoma viral oncogene homolog B (BRAF) is a common driver mutation in cancers of multiple tissue origins, including melanoma and glioma. BRAFV600E has also been implicated in neurodegeneration. The present study aims to characterize BRAFV600E during cell death and proliferation of three major cell types of the central nervous system: neurons, astrocytes, and microglia. Multiple primary cultures (primary cortical mixed culture) and cell lines of glial cells (BV2) and neurons (SH-SY5Y) were employed. BRAFV600E ...
Source: Cell Research - December 26, 2022 Category: Cytology Authors: Qing Ye Pranay Srivastava Nasser Al-Kuwari Xiqun Chen Source Type: research

ASAP Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.2c17802
Source: ACS Applied Materials and Interfaces - November 28, 2022 Category: Materials Science Authors: Seokhwan Chung, Yutaro Sugimoto, Jianxi Huang, and Miqin Zhang Source Type: research

Knockdown of lncRNA < em > HOXD-AS2 < /em > Improves the Prognosis of Glioma Patients by Inhibiting the Proliferation and Migration of Glioma Cells
CONCLUSION: HOXD-AS2 is an oncogenic lncRNA associated with the poor prognosis of glioma. Knockdown of HOXD-AS2 may reduce the growth of glioma, which may provide a new avenue for treatment.PMID:36408341 | PMC:PMC9668444 | DOI:10.1155/2022/9337647
Source: Evidence-based Complementary and Alternative Medicine - November 21, 2022 Category: Complementary Medicine Authors: Feng Chen Ru-Ru Zhao Qian Li Zhen-Hua Chen Chun Luo Source Type: research

Cyclin ‐dependent kinase subunit2 (CKS2) promotes malignant phenotypes and epithelial‐mesenchymal transition‐like process in glioma by activating TGFβ/SMAD signaling
ConclusionsWe identified CKS2 as a critical contributor to the gliomagenesis, which might provide a novel therapeutic target for inhibiting the spread and infiltration of glioma.
Source: Cancer Medicine - October 26, 2022 Category: Cancer & Oncology Authors: Fan Feng, Zongqing Zhao, Xuechang Cai, Xueyuan Heng, Ximeng Ma Tags: RESEARCH ARTICLE Source Type: research

Long non-coding RNA LUCAT1 regulates the RAS pathway to promote the proliferation and invasion of malignant glioma cells through ABCB1
In this study, the role of lung cancer associated transcript 1 (lncRNA LUCAT 1) in glioma occurrence and development, as well as its possible regulatory mechanism, was explored. We utilized the gene chip technology in the preliminary experiment, and based on the experiment results, selected LUCAT1（NONHSAT102745）, which was significantly upregulated in glioma, and ATP-binding cassette Subfamily B member l (ABCB1), which was significantly down-regulated in co-expression analysis, for study. Next, the expression of LUCAT1 and ABCB1 in cells and tissues was immediately evaluated. Subsequently, the cells were transfected wi...
Source: Cell Research - October 21, 2022 Category: Cytology Authors: Xia Wu Lvmeng Song Xiangrong Chen Yalan Zhang Shun Li Xiaoping Tang Source Type: research

TfR Aptamer Enhanced Blood ‐Brain Barrier Penetration of Biomimetic Nanocomplexes for Intracellular Transglutaminase 2 Imaging and Silencing in Glioma
Biomimetic nanocomplex (TMPsM) nanopartcles with dual blood-brain barrier (BBB)  targeting capability are prepared for simultaneous accurate diagnosis and effective treatment of glioma through single intracellular transglutaminase 2-triggered self-assembly aggregation-induced emission imaging and RNAi therapy. The dual BBB targeting biomimetic outer shells endow it with enhanc ed BBB penetration, prolonged blood circulation, and ensure the delivery of inner cores into brain tumor sites for theranostic agents release. AbstractEngineering a versatile nanocomplex integrating effective penetration of the blood-brain barrier (...
Source: Small - October 6, 2022 Category: Nanotechnology Authors: Juan Su, Zhipeng Yao, Zixuan Chen, Sisi Zhou, Zhi Wang, Hongping Xia, Songqin Liu, Yafeng Wu Tags: Research Article Source Type: research

The MicroRNA-106a/20b Strongly Enhances the Antitumour Immune Responses of Dendritic Cells Pulsed with Glioma Stem Cells by Targeting STAT3
CONCLUSIONS: This study indicted that the miR-106a/20b activation could be one of the important molecular mechanisms leading to enhance antitumour immune responses of GSC-mediated DCs, which downregulated the expression of STAT3 to alleviate its the inhibitory effect.PMID:36157880 | PMC:PMC9499788 | DOI:10.1155/2022/9721028
Source: Journal of Immunology Research - September 26, 2022 Category: Allergy & Immunology Authors: Hui Zhou Chengmei Sun Cong Li Shiting Hua Feng Li Ruichun Li Dongpeng Cai Yuxi Zou Yingqian Cai Xiaodan Jiang Source Type: research